


**CLAIMS:**

1. A compound of formula I:



or a pharmaceutically acceptable salt thereof wherein:

Ar is phenyl, benzisothiazol-3-yl or benzthiophen-3-yl, each of which bears substituent groups  $R^1$ ,  $R^2$  and  $R^3$ ;

- 10  $R^1$  is hydrogen, fluorine, chlorine, bromine,  $C_{1-6}$  alkyl,  $C_{3-6}$  cycloalkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{1-6}$  alkoxy,  $C_{2-6}$  alkenyloxy,  $C_{2-6}$  alkynyloxy, or  $C_{1-6}$  alkyl substituted by up to 5-fluorine atoms;

$R^2$  is hydrogen, fluorine, chlorine,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  alkyl substituted by up to 5 fluorine atoms or  $C_{1-4}$  alkoxy substituted by up to 5 fluorine atoms;

- 15  $R^3$  is hydrogen, fluorine, chlorine, methyl, methoxy, trifluoromethyl, difluoromethyl, trifluoromethoxy or difluoromethoxy;

- $Q^1$  is hydrogen; fluorine; chlorine; bromine;  $C_{1-6}$  alkyl;  $C_{3-6}$  cycloalkyl;  $C_{2-6}$  alkenyl;  $C_{2-6}$  alkynyl;  $C_{1-6}$  alkoxy;  $C_{2-6}$  alkenyloxy;  $C_{2-6}$  alkynyloxy;  $C_{1-6}$  alkyl substituted by up to 5-fluorine atoms; nitrile;  $COQ^4$  or  $CO_2Q^4$  where  $Q^4$  is hydrogen or  $C_{1-6}$  alkyl;  $NQ^5Q^6$ ,  $CONQ^5Q^6$  or  $SO_2NQ^5Q^6$  where  $Q^5$  is hydrogen or  $C_{1-6}$  alkyl and  $Q^6$  is hydrogen or  $C_{1-6}$  alkyl or  $Q^5$  and  $Q^6$  are joined to form either a 4-7 membered heterocyclic ring which may also contain one oxygen or one further nitrogen ring atom, which heterocyclic ring may optionally be substituted by up to 3 fluorine atoms or by  $CF_3$ , methyl, ethyl or hydroxyl; hydroxyl; nitro;  $SOQ^7$  or  $SO_2Q^7$  where  $Q^7$  is  $C_{1-4}$  alkyl;  $NQ^8COQ^9$ ,  $NQ^8CO_2Q^9$  or  $NQ^8SO_2Q^9$  where  $Q^8$  is hydrogen or  $C_{1-4}$ alkyl and  $Q^9$  is hydrogen or  $C_{1-4}$ alkyl or is joined to  $Q^8$  to form a 5-7 membered ring; a heteroaromatic ring of 5 ring atoms 1, 2, 3 or 4 of which may be nitrogen atoms or 1 or 2 of which are nitrogen atoms and 1 of which is an oxygen or sulfur atom or 1 of

- 30 -

which is an oxygen or sulfur atom, which heteroaromatic ring optionally being substituted by methyl, ethyl or hydroxyl; or a heteroaromatic ring of 6 ring atoms containing 1 or 2 nitrogen ring atoms or a phenyl group either of which is optionally substituted by 1 or 2 fluorine or chlorine atoms or C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy or trifluoromethyl groups;

Q<sup>2</sup> is hydrogen, fluorine, chlorine, nitrile, hydroxy, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkyl substituted by up to 5 fluorine atoms, or C<sub>1-4</sub> alkoxy substituted by up to 5 fluorine atoms;

Q<sup>3</sup> is hydrogen, fluorine, chlorine, methyl, methoxy, trifluoromethyl, difluoromethyl, trifluoromethoxy or difluoromethoxy;

or Q<sup>2</sup> and Q<sup>3</sup> are joined to form the residue of a 5, 6 or 7 membered carbocyclic ring;

R<sup>4</sup> is H or C<sub>1-4</sub> alkyl,

m is 0 or 1;


n is 0, 1 or 2; and

W is CH<sub>2</sub>, CHF, CH(OH) or CO.

2. A compound according to claim 1 wherein Ar represents benzisothiazol-3-yl or benzthiophen-3-yl, each bearing substituent groups R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup>, and m and n are both 0.

3. A compound according to claim 1 wherein Ar represents phenyl bearing substituent groups R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup>, m is 1 and n is 0.

4. A compound according to claim 1 of formula IIA:



(IIA)

- 31 -

or a pharmaceutically acceptable salt thereof;

wherein R<sup>13</sup> represents H and R<sup>14</sup> represents H, F or OH, or R<sup>13</sup> and R<sup>14</sup> together represent keto;

and Q<sup>1</sup>, Q<sup>2</sup>, R<sup>1</sup>, R<sup>2</sup> and R<sup>4</sup> are as defined in claim 1.

5

5. A compound according to any previous claim wherein Q<sup>1</sup> is selected from H, F, Cl, Br, CN, carboxamide, 5-membered heteroaryl and NQ<sup>5</sup>Q<sup>6</sup> where Q<sup>5</sup> and Q<sup>6</sup> complete a heterocyclic ring;

Q<sup>2</sup> is H, F or Cl;

10

Q<sup>3</sup> is H or F;

R<sup>1</sup> is H, F, methyl or CF<sub>3</sub>;

R<sup>2</sup> is H, F, methyl or CF<sub>3</sub>; and

R<sup>3</sup> is H.

15

6. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

7. A compound according to claim 1 for use in a method of treatment of the human body.

20

8. The use of a compound according to claim 1 for the manufacture of a medicament for treating or preventing a condition mediated by 5-HT<sub>2A</sub> receptor activity.

25

9. A method of treatment of a subject suffering from or prone to a condition mediated by 5-HT<sub>2A</sub> receptor activity which comprises administering to that subject an effective amount of a compound according to claim 1.

30